In 2017, a family’s worry brought a 78-year-old woman to Dr. Mark Supiano’s office: she was losing short-term memory. It was a familiar, unsettling concern, but during the routine check-up, a different alarm bell rang for the geriatrician at the University of Utah. Her blood pressure registered at 148/86 – elevated, despite already taking two medications to lower it.
That single number hinted at a complex web of potential contributors. Arthritis pain managed with anti-inflammatory medication, a diet rich in sodium, a lack of regular exercise, and a nightly glass or two of wine all played a role. Supiano discussed lifestyle changes, and the woman, along with her husband, joined a gym. She adjusted her diet, reduced her alcohol intake, and slowly, her systolic pressure began to fall, settling into the 130-140 range.
While an improvement, even that range was considered high according to updated guidelines released by the American Heart Association and the American College of Cardiology later that year. The top number in a blood pressure reading – the systolic – became the focal point, clinically the most important indicator of cardiovascular health. But the story didn’t end there.
By 2019, the patient received a diagnosis of mild cognitive impairment. Emerging medical evidence was beginning to illuminate a disturbing connection: hypertension, or high blood pressure, and the looming threat of dementia. Supiano admits he hadn’t been aggressive enough in his initial approach. He added a third medication, and her blood pressure finally dipped below 120 – a significant achievement.
The evolving guidelines for blood pressure control felt, to some, like a relentless lowering of the bar, a medical version of the classic game limbo: “How low can you go?” For over two decades, 140/90 had been considered acceptable. But the 2017 update, fueled by the groundbreaking SPRINT trial, dramatically shifted the landscape.
The SPRINT trial, involving adults over 50 with cardiovascular risk, revealed a startling truth: aggressively lowering systolic pressure below 120 significantly reduced the risk of heart attacks, strokes, cardiovascular disease, and overall mortality. The results were so compelling that researchers halted the study early, eager to share the life-altering recommendations. It became ethically untenable to withhold these benefits from participants.
The 2017 guidelines recommended medication for anyone with a systolic pressure exceeding 130. More recent revisions, released late last year, push for even stricter control, advocating for readings below 120 for patients at cardiovascular risk – and even considering that target “reasonable” for those without elevated risk. Readings once considered normal were now classified as hypertension.
Blood pressure naturally increases with age as arteries stiffen, forcing the heart to work harder. According to Dr. Erica Spatz of Yale School of Medicine, by 2023, roughly two-thirds of adults over 65 were considered hypertensive under the prevailing definition. But the latest revisions threatened to expand that number even further, potentially classifying millions more as needing treatment.
For Dr. Supiano, recent studies demonstrating cognitive benefits associated with lower blood pressure “tilted the scales,” particularly for older adults. “What’s good for the heart is good for the brain,” he stated, seeing these findings as a powerful motivator. Maintaining cognitive function, he believes, is often a higher priority for patients than simply extending lifespan.
The shift in guidelines has been largely embraced by major medical organizations, including the American Geriatrics Society, where Supiano serves as president. However, some physicians initially hesitated, mindful of the potential risks of over-treating blood pressure in older patients. Too low a pressure can cause dizziness, fainting, and dangerous falls.
Now, many doctors are adopting a more aggressive approach. Studies have shown that treating hypertension benefits even frail, elderly individuals. And while the SPRINT trial did show a slightly higher rate of falls in the intensive treatment group, the difference wasn’t statistically significant, particularly among those over 75.
A crucial component of the new approach is home monitoring. “Blood pressure is complicated,” explains Dr. Spatz. It fluctuates throughout the day, influenced by factors like wakefulness, meals, and even the weather. Readings can vary by 30 points or more within a single day, and are almost always higher in a clinical setting. “I don’t want to rely too heavily on a single measurement.”
Doctors are now asking patients to record their blood pressure twice daily for a week or two before appointments, and some are even prescribing 24-hour home monitors. The goal is to get a more accurate picture, accounting for “white coat syndrome” – anxiety triggered by medical settings – or even the stress of a parking dispute before an appointment.
Will patients embrace home monitoring and more aggressive treatment? Cardiologists acknowledge that hypertension, often asymptomatic, remains undertreated despite the updated guidelines. Cost is unlikely to be a barrier; generic medications are inexpensive, typically around $5 a month, and rarely interact with other medications commonly taken by seniors. Home monitors are also affordable, costing around $35, or slightly more for digital models.
While some side effects can be serious, most are “fortunately transient, reversible, and relatively mild.” However, the guidelines also face criticism. Dr. Rita Redberg advises her older patients on diet, exercise, and weight loss, but hesitates to prescribe medication to lower systolic pressure below 120 unless it’s significantly elevated. She believes patients are already overly preoccupied with their blood pressure.
“I encourage them to get out and enjoy life!” she exclaims. “Take a class! Go to a museum!” She worries that constant self-monitoring will confine patients to their homes. While trials and guidelines demonstrate population-level benefits, they can’t predict individual outcomes. Calculators used to estimate cardiovascular benefits from hypertension treatment haven’t been validated for those over 79 and don’t account for cognitive benefits.
For individuals with serious underlying illnesses, controlling blood pressure may not be a priority. Time is also a factor. A meta-analysis found that preventing a single stroke required treating 200 patients intensively for 1.7 years. Lowering already-high blood pressure is more straightforward and impactful than trying to push a reading of 130 below 120, requiring more medication and increasing the risk of side effects.
Dr. Supiano’s 78-year-old patient did achieve the target blood pressure and remained stable for six or seven years. Eventually, like many with mild cognitive impairment, she declined and was diagnosed with Alzheimer’s. Reflecting on the case, he wonders if the treatment “gave her a couple of years of good quality life,” or “delayed the progression.” Perhaps, he muses, he should have started the intensive treatment sooner.
